Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

Conditions:   Minimal Residual Disease;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia Interventions:   Biological: Daratumumab;   Procedure: Donor Lymphocyte Infusion;   Other: Laboratory Biomarker Analysis Sponsors:   Sumithira Vasu;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials